Accessibility Menu
Imugene logo

Imugene(OTC) IUGNF

Market Cap$48.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-41%
5 Year-99%
1 Year-52%
1 Month+11%
$0.10
+0%
+0.00Today
Imugene last closing stock price
MetricPriceDate
Last closeUSD 0.102026-07-24
Imugene stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+42.86%USD 0.072026-07-17
1 month+11.11%USD 0.092026-06-22
3 month-6.54%USD 0.112026-04-23
Year to date-61.54%USD 0.262025-12-31
1 year-52.38%USD 0.212025-07-24
3 year-95.48%USD 2.212023-07-25
5 year-98.82%USD 8.502021-07-23
Since inception-41.18%USD 0.172019-07-05

Imugene Financials at a Glance

Market Cap

$48.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.30M

Net Income (TTM)

-A$187.79M

EPS (TTM)

-$0.14

P/E Ratio

-0.69

Dividend

$0.00

Beta (Volatility)

-2.55 (Low)

Price

$0.10

Volume

6,218

Open

$0.08

Previous Close

$0.10

Daily Range

$0.08 - $0.10

52-Week Range

$0.06 - $0.31

Estimated Earnings Date

Sep 2, 2026

IUGNF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imugene

Imugene Limited is an Australian biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company aims to activate the immune systems of cancer patients to effectively combat malignant growths, with a strong emphasis on clinical-stage immuno-oncology.

Products and Services
  • HER-Vaxx: A vaccine targeting HER2-positive cancers, currently in Phase 1b/2 trials for gastric cancer
  • PD1-Vaxx: Designed to induce polyclonal antibodies that block PD-1 signaling in cancer treatment
  • CF33: An oncolytic virus developed from various vaccinia virus strains for solid tumor therapy
Growth Outlook
  • HER-Vaxx is progressing through clinical trials, potentially expanding treatment options for gastric cancer
  • Strategic partnerships with Celularity and Eureka Therapeutics enhance research capabilities and market reach
  • Continued investment in R&D supports the development of next-generation immunotherapies
Financial Highlights
  • Recent quarterly revenue reached AUD 8.068 million, indicating growth potential
  • Cash and cash equivalents stood at AUD 14.131 million, providing operational stability
  • Operating expenses totaled AUD 35.203 million, reflecting ongoing investment in R&D
Imugene Limited is positioned in the rapidly evolving field of immuno-oncology, with a focus on developing therapies that harness the body's immune system to fight cancer. The company's lead product, HER-Vaxx, is undergoing significant clinical evaluation, which could pave the way for new treatment options in the oncology space. The strategic collaborations with established firms like Celularity and Eureka Therapeutics further bolster Imugene's research capabilities, enhancing its potential for growth and innovation. Financially, the company has shown promising signs with a recent quarterly revenue of AUD 8.068 million, reflecting its ability to generate income as it advances its product pipeline. The cash reserves of AUD 14.131 million provide a buffer for ongoing operations and research initiatives, while the substantial investment in R&D underscores the commitment to developing cutting-edge therapies. Overall, Imugene Limited presents a compelling opportunity in the biotechnology sector, particularly for those interested in the future of cancer treatment.
AI Generated • Jul 9, 2026

Industry

Biotechnology

Sector

Health Care

Employees

23

CEO

Leslie Chong

Website

imugene.com

Headquarters

Sydney, NSW 2000, AU

IUGNF Financials

Key Financial Metrics (TTM)

Gross Margin

-65.91%

Operating Margin

-1960.77%

Net Income Margin

-1864.12%

Return on Equity

-134.65%

Return on Capital

-127.40%

Return on Assets

-86.46%

Earnings Yield

-1.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$48.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

489.72M

Volume

6.22K

Avg. Volume

15.69K

Financials (TTM)

Gross Profit

-A$3.91M

Operating Income

-A$178.91M

EBITDA

-A$178.95M

Operating Cash Flow

-A$150.43M

Capital Expenditure

-A$5.51M

Free Cash Flow

-A$155.94M

Cash & ST Invst.

A$14.13M

Total Debt

A$5.02M

Imugene Performance Analysis

Imugene annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
Imugene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-138.4%
Q22024-12-31140.6%
Q42025-06-30149.5%
Q22025-12-31-100.0%
Imugene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.17N/A
20232023-06-30AUD -0.14-16.7%
20242024-06-30AUD -0.47240.8%
20252025-06-30AUD -0.20-56.6%
Imugene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-11.8%
Q22024-12-3142.1%
Q42025-06-3057.2%
Q22025-12-31-38.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$5.20M

-164.5%

Gross Margin

0.00%

N/A

Market Cap

$48.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.79M

N/A

Employees

5

N/A

Net Income

-A$37.81M

+45.0%

EBITDA

-A$40.06M

+42.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$14.13M

-89.9%

Total Debt

A$5.02M

-22.6%

Accounts Receivable

A$4.41M

-78.4%

Inventory

A$1.67M

N/A

Long Term Debt

A$48.23K

-98.8%

Short Term Debt

A$4.97M

+115.1%

Return on Assets

-86.46%

N/A

Return on Invested Capital

-1.25%

N/A

Free Cash Flow

-A$25.96M

+56.7%

Operating Cash Flow

-A$25.96M

+46.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BSEMBioStem Technologies, Inc.
$3.82-4.74%
PRNAFAlterity Therapeutics Limited
$0.35-22.22%
VSBCVitaSpring Biomedical Co. Ltd.
$0.01+0.00%
HSCHFH-Source Holdings Ltd.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About IUGNF

What is the current price of Imugene?

Imugene is trading at $0.10 per share.

What is the 52-week range for Imugene?

Over the past 52 weeks, Imugene has traded between $0.06 and $0.31.

How much debt does Imugene have?

As of the most recent reporting period, Imugene reported total debt of A$6.98M.

How much cash does Imugene have on hand?

Imugene reported A$14.38M in cash and cash equivalents in its most recent financial results.

What is Imugene’s dividend yield?

Imugene does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services